Health Care • Medical/Dental Instruments
$32.00 ▼ -0.37
(-1.14%)
MKT CAP: $42.07B • VOL: 15.89M
52W L $31 52W H $51
MDLN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $28.43B | $25.51B | $23.23B |
| YoY Revenue Growth % | +11.5% | +9.8% | — |
| Gross Profit | $7.52B | $6.98B | $10.22B |
| Gross Margin % | 26.4% | 27.3% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.21B | $2.15B | $1.25B |
| Operating Margin % | 7.8% | 8.4% | 5.4% |
| Net Income (GAAP) | $1.16T | $0 | $0 |
| EBITDA (Normalized) | $2.57B | $2.43B | $2.09B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.74B | $1.77B | $1.69B |
| Capital Expenditures (CapEx) | $447.0M | $354.0M | $1.05B |
| Free Cash Flow (FCF) | $1.30B | $1.42B | $639.6M |
| FCF Margin % | 4.6% | 5.5% | 2.8% |
| Return on Invested Capital (ROIC %) | 8.2% | 5.2% | 5.9% |
| Cash & Short-Term Equivalents | $1.94B | $199.0M | $3.07B |
| Total Debt (Short + Long Term) | $12.48B | $16.42B | $6.52B |
| Total Stockholders' Equity | $10.74B | $16.52B | $13.38B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MDLN.